Dreisbach A W
Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Clin Pharmacol Ther. 2009 Nov;86(5):553-6. doi: 10.1038/clpt.2009.163. Epub 2009 Sep 23.
Chronic renal failure (CRF) has been shown, in animal models and clinical studies, to significantly reduce nonrenal clearance and to alter the bioavailability of predominantly metabolized drugs. Phase II reactions and drug transporters such as P-glycoprotein (P-gp) and organic anion transporting polypeptide (OATP) are also affected. High levels of parathyroid hormone (PTH), cytokines, and uremic toxins are implicated in some of these effects, which have a clinically significant impact on drug disposition and increase the risk of adverse drug reaction.
在动物模型和临床研究中已表明,慢性肾衰竭(CRF)会显著降低非肾清除率,并改变主要经代谢药物的生物利用度。II相反应以及药物转运蛋白,如P-糖蛋白(P-gp)和有机阴离子转运多肽(OATP)也会受到影响。高水平的甲状旁腺激素(PTH)、细胞因子和尿毒症毒素与其中一些作用有关,这些作用对药物处置具有临床显著影响,并增加药物不良反应的风险。